Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEMTRADA vs ADUHELM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
Treatment of relapsing forms of multiple sclerosis (MS), for patients who have had an inadequate response to two or more drugs indicated for MS.,Treatment of B-cell chronic lymphocytic leukemia (B-CLL) (off-label in many regions due to regulatory changes).
Treatment of Alzheimer's disease (FDA approved for patients with mild cognitive impairment or mild dementia stage of disease)
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of Ig G1 monoclonal antibodies.
Alemtuzumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via intracellular catabolism and proteolytic degradation.
Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific cytochrome P450 enzymes are involved.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine.
Not determined; likely low due to monoclonal antibody nature (primarily binds to CD52 antigen).
Approximately 99% bound, primarily to endogenous Ig G (via Fc Rn binding) and other plasma proteins; specific binding proteins include Fc Rn.
Approximately 0.1 L/kg; indicates limited extravascular distribution, primarily in serum and lymphoid tissues.
Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient.
IV only; not applicable (100% bioavailability via IV infusion).
Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy in pediatric patients (<18 years) have not been established.
Safety and efficacy have not been established in pediatric patients. No recommended dosing available.
No specific dose adjustment recommended; limited data available in patients ≥65 years; use with caution due to higher risk of infections and immune-mediated disorders.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
WARNING: SERIOUS AUTOIMMUNE CONDITIONS, INFUSION REACTIONS, AND MALIGNANCIES. Alemtuzumab can cause serious, potentially fatal autoimmune conditions (e.g., immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, autoimmune pancytopenia), infusion reactions, and an increased risk of malignancies including thyroid cancer, melanoma, and lymphoproliferative disorders. Only prescribers enrolled in a restricted distribution program should prescribe alemtuzumab.
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
Autoimmune conditions: Monitor for immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, and autoimmune pancytopenia.,Infusion reactions: Premedicate and monitor; reactions can be severe.,Infections: Increased risk due to lymphopenia; monitor for Listeria, herpes, and other opportunistic infections.,Malignancies: Monitor for thyroid cancer, melanoma, and lymphoproliferative disorders.,Vaccination: Avoid live vaccines during and after treatment.,Reproductive risk: Advise women of childbearing age to use contraception during and for 4 months after treatment.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H,Hypersensitivity reactions including angioedema and urticaria,Risk of seizures (reported in clinical trials),Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage
Hypersensitivity to alemtuzumab or any of its excipients.,Active infection (except minor localized infections).,Known history of progressive multifocal leukoencephalopathy (PML).,Concurrent treatment with other immunosuppressive therapies (not recommended).
Known hypersensitivity to aducanumab or any excipients of ADUHELM
No specific food interactions. Grapefruit and other CYP450 substrates are not relevant; alemtuzumab is not metabolized by CYP enzymes. Avoid alcohol due to potential immune effects.
No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes.
Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta. First trimester: Fetal Ig G exposure begins around week 13 of gestation; prior to that, transfer is minimal. Second and third trimesters: Ig G actively transported across placenta, increasing fetal exposure. Cases of fetal harm (spontaneous abortion, fetal death) reported. Risk of profound lymphopenia and other immune alterations in the newborn. No adequate human studies; animal studies show embryolethality and developmental toxicity.
No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk.
Excreted in human milk in low amounts; M/P ratio not available. Given the high molecular weight (approx. 150 k Da) and potential for immunosuppression in the nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Aducanumab is a large Ig G molecule; likely excreted into milk in low amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
Contraindicated; do not use in pregnancy. No dosing adjustment studies exist. If a woman becomes pregnant during treatment, discontinue therapy immediately and refer to high-risk obstetrics. No pharmacokinetic data are available to suggest dose changes in pregnancy; however, altered volume of distribution and clearance may occur but are not characterized.
No pharmacokinetic data during pregnancy. Dose adjustments not established. Administer same dose as non-pregnant adults (10 mg/kg IV monthly after titration) unless significant infusion reactions occur.
Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS). Administer via IV infusion over 4 hours for 5 consecutive days (first course) and 3 consecutive days (second course, 12 months later). Premedicate with corticosteroids (e.g., methylprednisolone 1 g IV) for 3 days each course to mitigate infusion reactions. Monitor for autoimmune adverse effects: immune thrombocytopenia (ITP), thyroid disorders, nephropathies. Obtain baseline and monthly CBC, serum creatinine, urinalysis with microscopy, and thyroid function for 48 months after last dose. Vaccinate for varicella zoster virus (VZV) at least 6 weeks prior if seronegative; avoid live vaccines during and after treatment. Pregnancy category C—contraindicated in pregnancy; effective contraception required during and 4 months after treatment.
ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available.
This drug is given as an intravenous infusion for five days in a row for the first course, and three days in a row one year later. Each infusion takes about 4 hours.,You will receive steroid medications before each infusion to reduce the risk of infusion reactions (fever, chills, rash, breathing problems).,Serious side effects include autoimmune conditions affecting blood cells (low platelets), thyroid, or kidneys. You need monthly blood and urine tests for at least four years after the last dose.,You may be at higher risk for infections; report any signs of infection (fever, cough, painful urination) immediately.,Do not receive live vaccines (e.g., chickenpox, nasal flu vaccine) during treatment and for at least 12 months after.
This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing.,Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months.,MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA).,Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures.,Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk.,Do not drive or operate heavy machinery if you experience dizziness or visual disturbances.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Store vials in refrigerator and protect from light; do not freeze or shake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEMTRADA vs ADUHELM, answered by our medical review team.
LEMTRADA is a Monoclonal Antibody that works by Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.. ADUHELM is a Anti-Amyloid Beta Monoclonal Antibody that works by Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEMTRADA and ADUHELM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEMTRADA is: 12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.. The standard adult dose of ADUHELM is: 10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEMTRADA and ADUHELM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEMTRADA is classified as Category C. Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an IgG1 monoclonal antibody that crosses the placenta. First trimester: Fetal IgG exposure begins around week 13 of. ADUHELM is classified as Category C. No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal repr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.